Abacus Life is structurally misunderstood and undervalued
The bull case argued for Abacus Life is that its high-volume, thin-margin model is highly effective, and its risk is misunderstood because it immediately offloads policy liabilities to private credit.
The argument
The speaker argued that a short report criticizing Abacus for overpaying for policies is fundamentally flawed because the company does not hold these policies on its balance sheet. Furthermore, the company is successfully pivoting toward recurring management fees via gated mutual funds and has demonstrated massive markup potential by securitizing policies into asset-backed securities.
The thesis, stress-tested
✓ What validates it
- ✓Issuance of larger face-value asset-backed securities with high markups
- ✓Growth in recurring revenue from management fees toward the 70% target
▸ Risks discussed
- ▸Biotech breakthroughs in longevity could hurt the returns of their gated mutual funds
- ▸A small portion (15%) of their book is held longer than a year, exposing them to some longevity risk
Hear it yourself
"One of the acquisitions they did is they bought a mutual fund company and they're creating these gated mutual funds saying instead of having private credit get 11 and a half percent uncorrelated, then individual retail investors in a gated mutual fund have a chance to get 11 and a half percent uncorrelated."
00:00 / 00:18